deltatrials
Completed PHASE2 NCT00002621

Interferon Alfa in Treating Children With HIV-Related Cancer

A Phase II Study of Alpha Interferon (alphaIFN) In HIV-Related Malignancies - A Pediatric Oncology Group Wide Study

Sponsor: Children's Oncology Group

Conditions Leukemia Lymphoma Unspecified Childhood Solid Tumor, Protocol Specific
Interventions recombinant interferon alfa
Updated 5 times since 2017 Last updated: Jul 23, 2014 Started: Dec 31, 1994 Primary completion: Jul 31, 2002 Completion: Sep 30, 2005

Listed as NCT00002621, this PHASE2 trial focuses on Leukemia and Lymphoma and remains completed. Sponsored by Children's Oncology Group, it has been updated 5 times since 1994, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 19 months · monthly snapshotCompleted

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Dec 1994

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Children's Oncology Group
  • National Cancer Institute (NCI)
Data source: Children's Oncology Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations